Cardiovascular Calcification Market Report 2026

The cardiovascular calcification market size has grown strongly in recent years. It will grow from $1.9 billion in 2025 to $2.05 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to aging population growth, rising prevalence of cardiovascular diseases, expansion of diagnostic imaging infrastructure, increased use of ct and mri systems, growing awareness of vascular calcification risks.

The cardiovascular calcification market size is expected to see strong growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing demand for precision cardiovascular diagnostics, rising adoption of AI-assisted imaging analysis, expansion of minimally invasive diagnostic procedures, growing investments in preventive cardiology, increasing focus on early intervention strategies. Major trends in the forecast period include increasing adoption of advanced cardiovascular imaging modalities, rising use of calcium scoring and risk stratification tools, growing integration of AI in diagnostic imaging, expansion of catheter-based diagnostic technologies, enhanced focus on early disease detection.

The increasing prevalence of cardiovascular diseases is anticipated to accelerate the expansion of the cardiovascular calcification market in the coming years. Cardiovascular diseases include conditions that affect the heart and blood vessels, resulting in issues such as heart disease, stroke, and elevated blood pressure. The growth in cardiovascular diseases is fueled by sedentary lifestyles and unhealthy dietary patterns, which heighten risks including hypertension, obesity, and arterial deterioration. Cardiovascular calcification contributes to cardiovascular disease management by acting as an indicator of atherosclerosis and plaque accumulation, enabling early identification of heart and vascular damage and supporting preventive or therapeutic measures. For example, in August 2025, according to the National Institutes of Health, a US-based government agency, cardiovascular prevalence is projected to increase by 90% between 2025 and 2050, mortality by 73%, and DALYs by 55%, with deaths rising from 20.5 million to 35.6 million. Therefore, the increasing prevalence of cardiovascular diseases is advancing the growth of the cardiovascular calcification market.

Leading companies operating in the cardiovascular calcification market are concentrating on developing innovative solutions, such as targeted intravascular shockwave energy delivery technologies, to enhance the treatment of heavily calcified lesions by improving lesion crossing capability, vessel flexibility, and procedural success rates. Targeted intravascular shockwave energy delivery technology is a catheter-based treatment that releases controlled acoustic pressure waves inside blood vessels to break apart calcified plaque while preserving surrounding soft tissue and maintaining vessel structure. For example, in March 2025, Shockwave Medical Inc., a US-based medical device company, introduced a new forward intravascular lithotripsy platform in the US aimed at improving the management of difficult-to-cross calcified lesions. The platform applies forward-directed sonic pressure waves to fracture calcium in calcified peripheral artery lesions without balloon inflation. It is designed to enable safer catheter navigation and vessel modification in complex PAD conditions such as CLTI, delivering improved outcomes compared to conventional tools. Key benefits include 99% technical success, low complication rates with only 1.1% major events, reduced risks of perforation or embolization, and greater efficiency for below-the-knee procedures, as demonstrated in FORWARD PAD trial results.

In May 2024, Johnson & Johnson, a US-based pharmaceutical firm, acquired Shockwave Medical for an undisclosed amount. Through this transaction, Johnson & Johnson sought to strengthen its capabilities in treating calcified arterial conditions and broaden its cardiovascular intervention portfolio by incorporating Shockwave’s intravascular lithotripsy (IVL) technologies and development pipeline, reinforcing its market position in calcification-focused therapies. Shockwave Medical Inc. is a US-based company specializing in addressing severe cardiovascular calcification through proprietary IVL technology.

Major companies operating in the cardiovascular calcification market are Abbott Laboratories, Medtronic plc, Siemens Healthineers AG, Fujifilm Holdings Corporation, Royal Philips Healthcare, GE HealthCare Technologies Inc., Boston Scientific Corporation, Shimadzu Corporation, HeartFlow Inc., Aidoc Ltd., Neusoft Medical Systems Co. Ltd., Medis Medical Imaging Systems B.V., Pie Medical Imaging B.V., Canon Medical Systems Corporation, Keya Medical Technology Co. Ltd., Coreline Soft Co. Ltd., FastWave Medical Inc., Cleerly Inc., United Imaging Healthcare Co. Ltd., Zebra Medical Vision Ltd., Circle Cardiovascular Imaging Inc.

Tariffs are influencing the cardiovascular calcification market by increasing costs of imported imaging systems, diagnostic catheters, software platforms, and advanced sensors used in ct, mri, and intravascular imaging. Hospitals and cardiac centers in North America and Europe are most affected due to reliance on imported medical devices, while Asia-Pacific faces cost pressures on high-end imaging equipment imports. These tariffs are increasing capital expenditure and delaying technology upgrades. However, they are also supporting localized device manufacturing, regional software development, and increased investment in domestic diagnostic innovation.

The cardiovascular calcification market research report is one of a series of new reports that provides cardiovascular calcification market statistics, including cardiovascular calcification industry global market size, regional shares, competitors with a cardiovascular calcification market share, detailed cardiovascular calcification market segments, market trends and opportunities, and any further data you may need to thrive in the cardiovascular calcification industry. This cardiovascular calcification market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiovascular calcification refers to the gradual buildup of calcium phosphate deposits within blood vessels and heart valves, resulting in tissue stiffening, reduced elasticity, and compromised mechanical function of cardiovascular structures. This disease process interferes with normal circulation and cardiac performance, substantially increasing the likelihood of atherosclerosis, valve narrowing, high blood pressure, heart failure, and serious cardiovascular events.

The primary product types for cardiovascular calcification management include imaging systems, atherectomy devices, stents, and transcatheter valves. Imaging systems are advanced diagnostic tools used to visualize and evaluate calcified cardiovascular tissues to support precise treatment planning. These systems enable diagnostic approaches such as computed tomography calcium scoring, echocardiography, intravascular ultrasound, and biomarker analysis. The applications include coronary artery disease, aortic valve stenosis, peripheral artery disease, and vascular calcification associated with chronic kidney disease, and the end users are hospitals, ambulatory surgical centers, cardiac clinics, and dialysis and nephrology centers.

The cardiovascular calcification market consists of sales of imaging systems, intravascular ultrasound devices, computed tomography scanners, magnetic resonance imaging systems, optical coherence tomography devices, catheter-based diagnostic tools, calcium scoring software, and contrast agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.